Adenosine deaminase (ADA) perpetuates chronic inflammation by degrading extracellular adenosine which is toxic for lymphocytes. ADA has two distinct conformations: open form and closed form [1]. From the crystal structures with various ligands, the non-nucleoside type inhibitors bind to the active site occupying the critical water-binding position and sustain the open form of apo-ADA. In contrast, substrate mimics do not occupy the critical position, and induce the large conformational change to the closed form. However, it is difficult to predict the binding of (+)-erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA), as it possesses characteristic parts of both the substrate and the non-nucleoside inhibitors. The crystal structure shows that EHNA binds to the open form through a novel recognition of the adenine base accompanying conformational change from the closed form of the PR-ADA complex in crystalline state [2]. The open form crystal structure of the EHNA-ADA complex supports our hypothesis that the occupancy at the trigger-water-position is critical for determining the open/closed conformational alternation, rather than the nucleoside framework binding. We believe that the structural penetration of the EHNA-ADA complex and structural comparison of the other inhibitor-ADA complexes will support the discovery of novel ADA inhibitors by structure-based drug design.
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[1] T. Kinoshita, et al, Biochemistry 44, 2005, 10562- Protein kinase CK2alpha is a highly pleiotropic serine/ threonine protein kinase. CK2alpha plays important roles in cell growth, proliferation, and survival, while it is highly expressed in a wide variety of tumors.(1) Furthermore, CK2alpha is a target protein for glomerulo nephritis (GN) therapy, because an administration of either anitisense oligodeoxynucleotide against CK2alpha or low molecular weight CK2alpha-specific inhibitors effectively prevents the progression of renal pathology in the rat GN models. (2) To design a novel and potent CK2alpha inhibitor, we determined four X-ray crystal structures of CK2alpha-inhibitor complexes (cc-04791, cc-04820, apigenin, ellagic acid), and measured enzyme kinetic parameters using ITC (Isothermal Titration Calorimetry) for the respective
